NCT06413316Completed
ABC-CT Pre-School Feasibility Study
Autism Biomarkers Consortium for Clinical Trials (ABC-CT) Pre-School Feasibility Study
Source: ClinicalTrials.gov · Last updated 2 Jul 2025
Brief summary (registry, in English)
This is a multicenter study that aims to determine whether the EEG and ET experiments studied in the ABC-CT Phase 1 and ABC-CT Confirmation studies can be successfully used with 3-5-year-old children and to determine the viability of these measures as potential biomarkers in 3-5-year-old children with ASD. Blood (DNA) samples will be collected from participants with ASD and biological parents for future genomic analyses, and raw, processed, and analyzed data will be shared to create a community resource accessible for use by all qualified investigators. These objectives are designed to advance the long term objective of developing promising biomarkers via the FDA Biomarker Qualification Program. This feasibility study aims to enroll 25 ASD and 25 TD eligible participants who are 3-5 years old.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 50 (actual)
- First submitted
- 8 May 2024
- Start date
- 2 Jul 2024
- Primary completion date
- 30 Jun 2025
- Lead sponsor
- Yale University
- Diseases
- Autism
- NCT number
- NCT06413316
What you commit to
- Study type: Observational
- Participants enrolled: 50
- From 2 Jul 2024 to the primary completion date, 30 Jun 2025
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Children who are taking neurological or psychiatric medications that are not stable on prescription or dose for 8 weeks prior to D1.
- Medication is not exclusionary. Children taking neurological or psychiatric medications, including anti epileptics and psychopharmacological agents, must be stable on the medication and dose for 8 weeks prior to D1.
Other illness
- Known genetic or neurological syndrome with an established link to autism (in addition to ASD for ASD participants)
- This does not include events in which the link to ASD is less well known/established (e.g., 16p11.2 CNVs, CHD8 mutations, Trisomy 21, 22q deletion syndrome, Dup 15q Syndrome).
- Specific cases will be discussed with the clinical team who will make a final determination, as needed.
- History of epilepsy or seizure disorder
- This does not include history of simple febrile seizures or if the child is seizure free (regardless of the seizure type) for the past year.
- Motor or sensory impairment that would interfere with the valid completion of study measures including significant hearing or vision impairment not correctable by a hearing aid or glasses/contact lenses. Children who wear bifocal or progressive lenses are not eligible.
- History of significant prenatal/perinatal/birth injury as defined by birth \<36 weeks AND weight \<2000 grams (approximately 4.5.lbs).
- History of neonatal brain damage. (e.g., with diagnosed hypoxic or ischemic event).
- Active psychiatric disorder (depression, anxiety, ADHD, etc.) and/or any current treatment (medication or other treatment) for a psychiatric condition.
- Participants will be screened using the (ECI-5 or CSI-4). Due to the instrument's high sensitivity and potential for false positives, any score in the clinical range will be reviewed by research staff for determination of eligibility.
Other
- For All Subjects:
- Any other factor that the investigator feels would make assessment or measurement performance invalid.
- For ASD Participants (only):
- 1\. Any known environmental circumstances that is likely to account for the picture of autism in the proband (severe nutritional or psychological deprivation etc.)
- For TD Participants (only):
- Known historical diagnosis of ASD or a sibling with ASD.
- Criteria score in the ASD range on the BOSA/ADOS
Who the study is looking for
- For All Subjects:
- Children (regardless of biological sex) Age 3 - 5. Participants must be able to complete the study before turning 6.
- Written parental permission will be obtained prior to any study procedures. Child verbal assent will be obtained.
- IQ 60-150 (ASD) and 80-150 (TD) as assessed by the Differential Ability Scales - 2nd Edition or developmental level via Mullen Scales of Early Learning Composite (ELC).
- Participant and parent/guardian must be English speaking.
- For ASD Participants (only):
- Diagnosis of ASD based on Diagnostic and Statistical Manual of Mental Disorders (DSM-5), the BOSA or Autism Diagnostic Observation Schedule (ADOS-2) and short form (ADI-R) scored age appropriately. Diagnostic evaluations will be completed by research staff and supervised by a licensed psychologist.
- If parents are biological, a minimum of the child and one parent will be required to consent to the blood draw procedure. It is preferred that the child and both biological parents participate in the blood draw procedure. The inability to obtain blood samples will not be exclusionary.
Age in the registry: 3 years to 5 years · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Boston Children's Hospital Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
| Duke University Coordinator of this site? Confirm its status | Durham | United States | Unknown status |
| Children's Hospital Los Angeles Coordinator of this site? Confirm its status | Los Angeles | United States | Unknown status |
| Yale Child Study Center Coordinator of this site? Confirm its status | New Haven | United States | Unknown status |
| University of Washington Coordinator of this site? Confirm its status | Seattle | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.